会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 12. 发明授权
    • Bioresorbable controlled-release composition
    • 生物可吸收的控释组合物
    • US08999389B2
    • 2015-04-07
    • US12224942
    • 2007-03-14
    • Hans LennernäsNiklas Axén
    • Hans LennernäsNiklas Axén
    • A61K9/00A61K9/16
    • A61K9/0024A61K9/0034A61K9/1611A61K9/1694
    • A novel method for the preparation of a highly densified and at least partly, preferably fully or almost fully hydrated ceramic for use in the preparation of a pharmaceutical composition notably for controlled-release of one or more therapeutically, prophylactically and/or diagnostically active substance. The method involves a concomitant step of hydrating and densifying a bioresorbable and hydratable ceramic such as calcium sulphate. The invention also relates to compositions comprising such a highly densified ceramic. The pharmaceutical composition is useful for targeted and controlled local prolonged release of active substances, e.g. anti-cancer agents, whereby the spectrum and severity of side effects are minimized due to an optimized local concentration-time profile.
    • 一种用于制备高致密化和至少部分,优选完全或几乎完全水合的陶瓷的新方法,用于制备药物组合物,特别是用于控制释放一种或多种治疗,预防和/或诊断活性物质。 该方法包括水合和致密化生物可再吸收和可水合的陶瓷如硫酸钙的伴随步骤。 本发明还涉及包含这种高密度陶瓷的组合物。 药物组合物可用于靶向和受控局部延长的活性物质的释放,例如, 由于优化的局部浓度 - 时间曲线,抗癌剂的副作用的频谱和严重程度被最小化。
    • 13. 发明授权
    • Method for treating prostate diseases based on local delivery of active substances
    • 基于活性物质的局部递送治疗前列腺疾病的方法
    • US08936809B2
    • 2015-01-20
    • US11910162
    • 2006-03-31
    • Hans LennernäsBo LennernäsJonas HugossonNiklas Axén
    • Hans LennernäsBo LennernäsJonas HugossonNiklas Axén
    • A61K9/22A61K49/04A61K49/00A61K47/00A61K31/56A61K48/00A61K38/00A61K9/16
    • A61K9/1647
    • A method for treating prostate related diseases in a subject, the method comprising i) optionally administering to subject an initial boost dose of one or more active substances and/or prodrugs, and ii) administering locally into the prostate a controlled release pharmaceutical composition comprising one or more active substances in a biodegradable ceramic carrier. The biodegradable hydrating ceramic may be selected from the group consisting of non-hydrated or hydrated calcium sulphate, calcium phosphate, calcium carbonate, calcium fluoride, calcium silicate, magnesium sulphate, magnesium phosphate, magnesium carbonate, magnesium fluoride, magnesium silicate, barium sulphate, barium phosphate, barium carbonate, barium fluoride, barium silicate, or mixtures thereof. In a specific embodiment, the biodegradable hydrating ceramic is non-hydrated or hydrated calcium sulphate.
    • 一种用于治疗受试者中前列腺相关疾病的方法,所述方法包括i)任选地施用受试者初始增强剂量的一种或多种活性物质和/或前药,以及ii)局部施用于前列腺中的控释药物组合物,其包含一种 或更多的活性物质在可生物降解的陶瓷载体中。 可生物降解的水合陶瓷可以选自非水合或水合硫酸钙,磷酸钙,碳酸钙,氟化钙,硅酸钙,硫酸镁,磷酸镁,碳酸镁,氟化镁,硅酸镁,硫酸钡, 磷酸钡,碳酸钡,氟化钡,硅酸钡或其混合物。 在一个具体实施方案中,可生物降解的水合陶瓷是非水合或水合硫酸钙。